
FLDM
Healthcare · Diagnostics & Research · $286.4M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 17, 2022 | After the close | -0.28 | -0.12 | +57.1% |
| Nov 8, 2021 | After the close | -0.11 | -0.07 | +36.4% |
| Aug 5, 2021 | After the close | -0.09 | -0.12 | -41.2% |
| May 6, 2021 | After the close | -0.04 | -0.15 | -233.3% |
| Feb 10, 2021 | After the close | 0.01 | -0.13 | -1400.0% |
| Nov 5, 2020 | After the close | -0.12 | 0.03 | +126.1% |
| Aug 6, 2020 | After the close | -0.14 | -0.07 | +50.0% |
| May 7, 2020 | After the close | -0.10 | -0.13 | -23.8% |
| Feb 10, 2020 | After the close | -0.09 | -0.03 | +66.7% |
| Nov 5, 2019 | After the close | -0.09 | -0.09 | 0.0% |
| Aug 1, 2019 | After the close | -0.07 | -0.10 | -36.4% |
| May 2, 2019 | After the close | -0.10 | -0.14 | -44.8% |
| Feb 7, 2019 | After the close | -0.20 |
Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand…
| -0.06 |
| +69.2% |
| Nov 1, 2018 | After the close | -0.18 | -0.13 | +27.8% |
| Aug 2, 2018 | After the close | -0.23 | -0.23 | +3.7% |
| May 3, 2018 | After the close | -0.30 | -0.21 | +31.0% |
| Feb 8, 2018 | After the close | -0.25 | -0.15 | +38.4% |